{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:47Z","timestamp":1792511927376,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019533","name":"Moderna, Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019533","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Influenza A viruses pose a persistent pandemic threat. We report safety, reactogenicity, and immunogenicity findings for mRNA-1018 pandemic influenza vaccine candidates from a phase 1\/2 study in healthy adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In part A, participants were randomized to receive 1 of 4 mRNA-1018 candidates at 1 of 3 dose levels across 2 influenza A groups: (1) H5N8\/H5-only or (2) H7N9\/H7-only. Part B participants were randomized to receive H5-only-CG. The primary objectives were to evaluate the safety and reactogenicity. The secondary objectives included evaluation of humoral immunogenicity through day 205 by hemagglutination inhibition (HAI), neuraminidase inhibition, and microneutralization assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Parts A and B comprised 1195 and 304 dosed participants, respectively. Overall, solicited local adverse reactions (ARs) within 7 days of vaccination occurred in 76.8% of participants across vaccine candidates and dose levels, most commonly injection-site pain. Solicited systemic ARs were reported in 62.8% of participants, most frequently fatigue and headache. Postvaccination immune responses, assessed absolutely, by HAI titers and dynamically, by seroconversion rates, tended to increase with vaccine dose. H5-based candidates induced stronger strain-specific HAI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vaccine candidates were sufficiently well tolerated and immunogenic. Further development of mRNA pandemic influenza vaccines is warranted.<\/jats:p>\n                    <jats:p>Clinical Trials Registration. NCT05972174<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag278","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:49:42Z","timestamp":1776858582000},"page":"e598-e610","source":"Crossref","is-referenced-by-count":1,"title":["A Phase 1\/2 Dose-Ranging Safety and Immunogenicity Study of mRNA-Based Candidate Pandemic Influenza Vaccines in Healthy Adults"],"prefix":"10.1093","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0295-6893","authenticated-orcid":false,"given":"Catherine A","family":"Cosgrove","sequence":"first","affiliation":[{"name":"Institute of Infection and Immunity & Vaccine Institute, City St George\u2019s, University of London, United Kingdom & St George\u2019s University Hospital NHS Trust , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Avanesov","sequence":"additional","affiliation":[{"name":"Moderna, Inc. Clinical Operations and Clinical Biomarkers, , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dondi","family":"Rust","sequence":"additional","affiliation":[{"name":"Moderna, Inc. Clinical Operations and Clinical Biomarkers, , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6126-0489","authenticated-orcid":false,"given":"Seun","family":"Osibajo","sequence":"additional","affiliation":[{"name":"Moderna, Inc. Clinical Operations and Clinical Biomarkers, , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingston","family":"Kang","sequence":"additional","affiliation":[{"name":"Moderna, Inc. Clinical Operations and Clinical Biomarkers, , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Leav","sequence":"additional","affiliation":[{"name":"Moderna, Inc. Clinical Operations and Clinical Biomarkers, , Cambridge, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ODYSSEY Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amardeep","family":"Heer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeka","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Palfreeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Rampling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orod","family":"Osanlou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Rivard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelia","family":"Sanchez-Crespo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fierro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Earl F","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie Ann","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"key":"2026100713431113800_ciag278-B1","author":"Centers for Disease Control and Prevention"},{"key":"2026100713431113800_ciag278-B2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/v10090497","article-title":"Zoonotic potential of influenza a viruses: a comprehensive overview","volume":"10","author":"Mostafa","year":"2018","journal-title":"Viruses"},{"key":"2026100713431113800_ciag278-B3","author":"Centers for Disease Control and Prevention"},{"key":"2026100713431113800_ciag278-B4","author":"Centers for Disease Control and Prevention"},{"key":"2026100713431113800_ciag278-B5","article-title":"On the brink: H5N1 and the risk to human health","volume":"46","author":"The Lancet Regional Health \u2013 Americas","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"2026100713431113800_ciag278-B6","author":"Centers for Disease Control and Prevention"},{"key":"2026100713431113800_ciag278-B7","article-title":"Enhancing the response to avian influenza in the US and globally","volume":"46","author":"Bartlett","year":"2025","journal-title":"Lancet Reg Health Am"},{"key":"2026100713431113800_ciag278-B8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41541-024-00988-9","article-title":"An mRNA vaccine candidate encoding H5HA clade 2.3.4.4b protects mice from clade 2.3.2.1a virus infection","volume":"9","author":"Chiba","year":"2024","journal-title":"NPJ Vaccines"},{"key":"2026100713431113800_ciag278-B9","author":"GlaxoSmithKline"},{"key":"2026100713431113800_ciag278-B10","author":"Seqirus Inc"},{"key":"2026100713431113800_ciag278-B11","author":"Sanofi Pasteur"},{"key":"2026100713431113800_ciag278-B12","author":"GlaxoSmithKline"},{"key":"2026100713431113800_ciag278-B13","author":"Seqirus Inc"},{"key":"2026100713431113800_ciag278-B14","author":"Sanofi Pasteur Inc"},{"key":"2026100713431113800_ciag278-B15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol J"},{"key":"2026100713431113800_ciag278-B16","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126847","article-title":"A phase 3 randomized safety and immunogenicity trial of mRNA-1010 seasonal influenza vaccine in adults","volume":"50","author":"Soens","year":"2025","journal-title":"Vaccine"},{"key":"2026100713431113800_ciag278-B17","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2416779","article-title":"Efficacy, immunogenicity, and safety of modified mRNA influenza vaccine","volume":"393","author":"Fitz-Patrick","year":"2025","journal-title":"N Engl J Med"},{"key":"2026100713431113800_ciag278-B18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaf695.012","article-title":"229. mRNA-1010, an mRNA-based influenza vaccine, is safe and efficacious in adults aged \u226550 years","volume":"13","author":"Malkin","year":"2026","journal-title":"Open Forum Infect Dis"},{"key":"2026100713431113800_ciag278-B19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nrmicro2613","article-title":"Influenza A viruses: new research developments","volume":"9","author":"Medina","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"2026100713431113800_ciag278-B20","author":"ClinicalTrials.gov"},{"key":"2026100713431113800_ciag278-B21","author":"Food and Drug Administration"},{"key":"2026100713431113800_ciag278-B22","author":"Food and Drug Administration"},{"key":"2026100713431113800_ciag278-B23","author":"Food and Drug Administration"},{"key":"2026100713431113800_ciag278-B24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049704","article-title":"A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine","volume":"7","author":"Couch","year":"2012","journal-title":"PLoS One"},{"key":"2026100713431113800_ciag278-B25","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"2026100713431113800_ciag278-B26","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"2026100713431113800_ciag278-B27","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"2026100713431113800_ciag278-B28","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac982","article-title":"Safety and immunogenicity of influenza A\/H5N8 virus vaccine in healthy adults: durability and cross-reactivity of antibody responses","author":"Neuzil","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026100713431113800_ciag278-B29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008761","article-title":"A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults","volume":"6","author":"Bart","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026100713431113800_ciag278-B30","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1093\/cid\/ciae173","article-title":"A phase 2 clinical trial to evaluate the safety, reactogenicity, and immunogenicity of different prime-boost vaccination schedules of 2013 and 2017 A(H7N9) inactivated influenza virus vaccines administered with and without AS03 adjuvant in healthy US adults","volume":"78","author":"Rostad","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026100713431113800_ciag278-B31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.vaccine.2020.11.051","article-title":"Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older","volume":"39","author":"Winokur","year":"2021","journal-title":"Vaccine"},{"key":"2026100713431113800_ciag278-B32","author":"ClinicalTrials.gov"},{"key":"2026100713431113800_ciag278-B33","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/infdis\/jir172","article-title":"Dose-sparing H5N1 A\/Indonesia\/05\/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study","volume":"203","author":"Langley","year":"2011","journal-title":"J Infect Dis"},{"key":"2026100713431113800_ciag278-B34","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/vaccines9121468","article-title":"Analyses of safety profile and homologous antibody responses to a mammalian cell-based, MF59-adjuvanted, A\/H5N1, pandemic influenza vaccine across four phase II\/III clinical trials in healthy children, adults, and older adults","volume":"9","author":"Versage","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2026100713431113800_ciag278-B35","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMc2405371","article-title":"Highly pathogenic avian influenza A(H5N1) virus infection in a dairy farm worker","volume":"390","author":"Uyeki Timothy","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag278\/68157636\/ciag278.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e598\/68157636\/ciag278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e598\/68157636\/ciag278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:43:21Z","timestamp":1791395001000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/3\/e598\/8662346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,25]]},"published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag278","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,4,25]]}}}